Johnson & Johnson ( JNJ 0.01%) has been a leading healthcare company in the world for decades, and it's one of the most ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

NEW YORK – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.Spravato is a first-of-its-kind medication to help manage ...

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...

In just over five minutes, Johnson & Johnson tackles the complicated nature of living with depression — both from the perspective of patients and caregivers — in a recently released short film.

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against treatment-resistant depression, giving biotechs hope that this type of drug will become a ...